article thumbnail

COVID-19 Vaccine Patent Infringement? The Battle Between Moderna and Pfizer/BioNTech Continues

Bill of Health

Moderna also licensed their mRNA technology from Cellscript LLC – University of Pennsylvania’s successor-in-interest to the 966 patent. Indeed, as made public, the U.S. government committed more than one billion dollars to Moderna for development of its COVID-19 vaccines.

article thumbnail

Unlocking the mRNA Platform Technology: Walking the Talk with Investment Protection

Bill of Health

By Aparajita Lath Two articles published last month in the BMJ analyze the public investment and financing of mRNA COVID-19 vaccines, highlighting the extensive government funding that has supported the development of mRNA technology from 1985 to 2022. government substantially de-risking the vaccine development process.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Using Contracts to Lessen Inequities in Access to Medicines in Pandemics and Epidemics

Bill of Health

Research funding contracts can help to safeguard against profound inequities in global allocation and distribution of lifesaving diagnostics, drugs, and vaccines. During large transnational public health crises, global demand soars for diagnostics, drugs, and vaccines. Using Contracts to Further Equity Goals.

article thumbnail

COVID ‘Compromise’ on International IP Underscores Need for New Approach

Bill of Health

It only narrowly modifies compulsory licenses of patents covering COVID vaccines. Moreover, it imposes additional restrictions on use of compulsory licenses. Moreover, Brazil’s new compulsory license law models another critical feature that domestic laws should have – a way around data exclusivity. Third, the U.S.

COVID-19 309
article thumbnail

Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna?

Bill of Health

The National Institutes of Health (NIH) is currently embroiled in a dispute over the ownership of patent rights to Moderna’s flagship mRNA COVID-19 vaccine (mRNA-1273). Failing to do so would be a missed opportunity for the public sector to have a say in the distribution and pricing of this critical medical technology.

article thumbnail

Strategic Maneuvers in Response to COVID-19 Denialist Laws and Policies

Bill of Health

Over the course of the COVID-19 pandemic, now entering its fourth year in 2023, legislators, executives, and judges at every level of government have sought measures to derail efficacious public health interventions. And that’s where they are wrong. Some victories came easy.

COVID-19 176
article thumbnail

Compliance Implications for the End of the Federal Public Health Emergency (PHE)

MedTrainer

The end of the federal Public Health Emergency (PHE) will reinstate regulations that have been absent for years… and many healthcare workers have never had to follow. There are plenty of compliance implications for the end of the Public Health Emergency on May 11, 2023 , and an assessment is a great place to start.